Status Awaiting development
Technology type Medicine
Decision None selected
Process TAG
ID number 3851

Provisional Schedule

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators 25 April 2022 - 23 May 2022
Expected publication 10 May 2023

Project Team

Project lead Kate Moore

Email enquiries

External Assessment Group Kleijnen Systematic Reviews Ltd


Key events during the development of the guidance:

Date Update
26 November 2021 Following a request received from the company, NICE will be undertaking an appraisal of Dabrafenib with trametinib for treating advanced BRAF V600 mutation-positive non-small-cell lung cancer. This was originally terminated guidance TA564. The appraisal is expected to start during April 2022 with a consultation on the draft scope. It is then anticipated that the final scope will be released along with an invitation to participate in the appraisal during mid-June 2022. The deadline for submissions is expected in approximately mid-August 2022.

For further information on our processes and methods, please see our CHTE processes and methods manual